Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials.
|
| Abstract |
LDL-C is the pivotal risk factor for atherosclerotic cardiovascular disease, and the benefit from LDL-C lowering is proportional to the magnitude of reduction. Clinical trials demonstrate that evolocumab reduces LDL-C levels by approximately 60% when measured at the trough of drug effect, which may underestimate cumulative LDL-C reduction. We obtained a time-averaged estimate of LDL-C lowering that included both peaks and troughs. Pooled analysis of 5 phase 2 trials included patients with hypercholesterolemia who received placebo or evolocumab (140 mg every 2 weeks [Q2W] or 420 mg monthly [QM]). Percent changes from baseline LDL-C and free serum PCSK9 were averaged across weeks 9-12. In 372 patients, time-averaged percent reduction from baseline in LDL-C with evolocumab vs placebo was 67.6% (95% CI: 63.9-71.3) with Q2W dosing and 65.0% (95% CI: 60.7-69.3) with QM dosing. The time-averaged measure yielded LDL-C reductions for evolocumab that exceeded measurements at the end of dosing intervals and may provide a better estimate of cardiovascular benefit during long-term therapy.
|
|---|---|
| Authors | Belinda Schludi, Robert P Giugliano, Marc S Sabatine, Frederick J Raal, Tamio Teramoto, Michael J Koren, Evan A Stein, Huei Wang, Maria Laura Monsalvo |
| Journal | Journal of clinical lipidology (J Clin Lipidol) 2022 Jul-Aug Vol. 16 Issue 4 Pg. 538-543 ISSN: 1933-2874 [Print] United States |
| PMID | 35760720 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't) |
| Copyright | Copyright © 2022. Published by Elsevier Inc. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!